Liquidia's chief medical officer sold 35,365 common shares on March 13, 2026 for about $1.28 million, at roughly $36.30 per share. This is a factual insider sale (≈$1.28M) that likely reflects personal liquidity rather than company-operational news and should have limited market impact, though it could be viewed slightly negative by some investors.
Liquidia's chief medical officer sold 35,365 common shares on March 13, 2026 for about $1.28 million, at roughly $36.30 per share. This is a factual insider sale (≈$1.28M) that likely reflects personal liquidity rather than company-operational news and should have limited market impact, though it could be viewed slightly negative by some investors.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
neutral
Sentiment Score
0.00
Ticker Sentiment
